Palisade Bio Receives Buy Recommendation from Stifel, Analyst Price Forecast Suggests 650.28% Upside

Stifel has initiated coverage of Palisade Bio (PALI) with a Buy recommendation, with an analyst price forecast suggesting a 650.28% upside from its latest closing price. The average one-year price target is $13.43/share, with projected annual revenue of $28MM and non-GAAP EPS of -$12.34. There are 87 funds or institutions reporting positions in PALI, with an average portfolio weight of 0.36%.